tissues. The relative level of Tspo mRNA was quantified using fluorescent intensity and visual 23 estimation of colorimetric staining. RT-PCR was used to confirm these mRNA levels in normal lung, 24 lung cancer, liver cancer and cervical cancer cell lines. There was a significant increase in the level of 25 transcription in liver, prostate, kidney and brain cancers while a significant decrease was observed 26 in cancers of the colon and lung. Quantitative RT-PCR confirmed that the mRNA levels of Tspo are 27 higher in a normal lung cell line than in a lung cancer cell line. An increase in the expression levels of 28 TSPO makes it a good diagnostic biomarker and TSPO could serve as a target for anticancer drug 29 development. 30
. In Grade II colonic adenocarcinoma, Tspo mRNA was localized 120 in the cytoplasm of tumour cells arranged as adenomatous glands or solid sheets (Figures 3E and F) . 121
Tspo mRNA was localized in the cytoplasm of tumour cells that are predominantly arranged as a 122 solid pattern of Grade III colonic adenocarcinoma (Figures 3G and H) . also shown an increase in TSPO protein in colonic adenocarcinoma compared to its normal 335 counterpart 24, 26 ; however, in our study we found no significant difference in Tspo mRNA 336 transcription in colon cancer, when compared to its normal counterpart. These differences in 337 expression may be attributed to differences in the nature of the studies. Thereafter, an aliquot of 2 µl was reverse transcribed to synthesize cDNA using a First Strand cDNA 391 Synthesis Kit (Roche Diagnostics GmbH, Manneheim, Germany) following the manufacturer's 392 protocol. Subsequently, the cDNA was used as a template to amplify part of the Tspo mRNA using 393 primers specific for the Tspo gene (primers were designed using the following sequence as template: 394 Accession Number: BT006949; TSPO F-5'-TTCACAGAGAAGGCTGTGGTTC-3' and TSPO 395 R-5'-GCCATACGCAGTAGTTGAGTGT-3') resulting in a 247 bp DNA fragment. PCR was 396 performed in GeneAmp® PCR System 9700 thermocycler (Applied Biosystems, Foster City, CA, 397 USA) using the following reaction components: 1X PCR Master Mix (Promega Corporation, 398
Madison, WI, USA), 1µM forward primer, 1µM reverse primer, 1,5 mM MgCl2, and 1.0 µl cDNA, 399 with an initial denaturation at 95 °C for 2 minutes followed by 30 cycles of denaturation at 95 °C for 400 30 seconds, annealing at 58 °C for 30 seconds and elongation at 72 °C for 1 minutes and a final 401 elongation at 72 °C for 1 minute. The PCR product was ligated into the pGEM-T Easy vector 402 intensity produced by the fluorescently labelled in situ hybridisation probes was measured and used 457 as an indicator of the level of Tspo mRNA. The levels of fluorescence were normalised using the 458 negative controls. Significant differences were determined using one-way analysis of variance 459 (ANOVA) followed by Tukey's multiple comparison test. A probability level of P <0.05 was 460 considered significant. The intensity of the colorimetric staining was assessed visually by assigning a 461 score to each sample based on the level of staining observed in the malignant cells. A score of 0 462
represented no staining, a score of 1 represented <10% of cells were stained, a score of 2 represented 463 10%-50% of cells were stained and finally, a score of 3 represented >50% of cells were stained. 464
Significant differences were determined using one-way analysis of variance (ANOVA) followed by 465
Tukey's multiple comparison test. A probability level of P <0.05 was considered significant. 466 
